Session: MON 37-82-Pheochromocytoma & Paraganglioma
Poster Board MON-50
Case Report: We report two patients admitted to Endocrinology department with adrenal incidentalomas. First patient has had ulcerativite colitis for 9 years and ankylosing spondylitis for 2 years. During her colonoscopy a stricture was found and abdominal CT was performed. On abdominal CT a left adrenal mass, 29 mm in diameter was diagnosed . She was receiving sulfasalazine 3 gr/d for ankylosing spondilitis. Second patient was receiving 4 gr/d sulfasalazine for the same indication with the first patient and he had an 15 mm left adrenal incidentaloma .
The 24-hour urinary catecholamines and metabolites were measured by high-performance liquid chromatography after urine specimens were acidified and hydrolyzed. First patient’s normetanephrine levels were measured twice and both were higher than the normal( 790.5 and 698 μg/d ; normal range 88-444 μg/d , 929 and 1290 mg/d creatinin). Urinary metanephrine and adrenaline levels remained normal. Urinary noradrenaline levels were higher than the normal ( 69,7 and 96,4 μg/d; normal range 20-81 μg/d). Plasma chromogranin A level was normal.
Second patient’s urinary normetanephrine and vanillylmandelic acid level was higher than normal (817.4 μg/d; normal range 88-444 μg/d and 16,1 mg/d; normal range 1,8-6,7 mg/d) and other urinary cathecolamines and metabolites were normal. Both patients were normotensive without antihypertensive medication. They had no history of hypertensive attacks, massive perspiration, palpitation, pallor or flushing. A false positive result in 24 hour urinary normetanephrine level was suspected but sulfasalazine treatment couldn’t stop because of active diseases in the spine.
Conclusions: We report biochemical misdiagnosis of pheochromocytoma in two patients being treated with sulfasalazine. Sulfasalazine is reported to cause false positive urinary cathecolamines Recognition of drugs that may interfere with assays of urinary normetanepfrine can avoid unnecessary surgical interventions and additional investigations.
Nothing to Disclose: BIA, PK, ARU, SG
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters